Earnings News - Candlesense

Intapp announces fourth quarter and fiscal year 2025 financial results

PALO ALTO, Calif.--(BUSINESS WIRE)--Intapp, Inc. (NASDAQ: INTA), a leading global provider of AI-powered solutions for professionals at advisory, capital markets, and legal firms, announced financi...

What potential risks or uncertainties were highlighted in the earnings call or press release that could impact the stock's volatility? How might the reported results affect the positioning of Intapp within AI-driven professional services, and could this lead to shifts in market share? What is the projected cash flow generation for FY 2026, and does it support potential dividend initiation or further investment initiatives?

Symbol: INTA

28 days ago

Read more businesswire

Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, tod...

What risk factors were highlighted in the earnings release (e.g., regulatory risk, technology adoption risk, reimbursement uncertainty) that could affect the valuation? Are there any upcoming catalyst events (e.g., data readouts, regulatory submissions, investor presentations) that could drive volatility in PLSE stock? What is the anticipated impact on the share price in the near term, given the sentiment score of 60 and the market's reaction to previous earnings releases?

Symbol: PLSE

28 days ago

Read more businesswire

Surf Air Mobility Reports Second Quarter 2025 Financial Results, Exceeding Revenue and Adjusted EBITDA Guidance

LOS ANGELES--(BUSINESS WIRE)--Surf Air Mobility Inc. (NYSE: SRFM) (the “Company” or “Surf Air Mobility”), a leading regional air mobility platform, today reported financial results for the second q...

How might this earnings release affect short‑term trading volume and volatility? What are the potential risks or downside scenarios that could affect the stock in the near term? Is there any guidance on capital expenditures, fleet expansion, or new market entry?

Symbol: SRFM

28 days ago

Read more businesswire

PublicSquare Reports Second Quarter 2025 Financial Results, Announces Strategic Repositioning to Accelerate Fintech Growth

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--PSQ Holdings, Inc. (NYSE: PSQH) (“PublicSquare,” or the “Company”), today reported financial results for the second quarter 2025 and announced a strategic re...

How might the market’s perception of this strategic shift influence PSQH’s stock valuation and price‑to‑earnings multiple? What is the anticipated timeline for achieving scalability and capital‑efficiency targets outlined in the initiative? How will the reallocation of resources toward fintech affect the performance of PSQH's legacy business lines?

Symbol: PSQH

28 days ago

Read more businesswire

Luminar Reports Q2’25 Financials

ORLANDO, Fla.--(BUSINESS WIRE)--Today, Luminar (NASDAQ: LAZR), a leading global automotive technology company, provided its quarterly business update and financial results for the second quarter of...

What is the expected impact of the Q2'25 results on the company's forward P/E and other valuation multiples? Did the management commentary address any risks or headwinds that traders should monitor going forward? What macroeconomic or industry trends (e.g., supply chain constraints, regulatory developments) were mentioned that could affect the company's near‑term outlook?

Symbol: LAZR

28 days ago

Read more businesswire

Fractyl Health Announces Second Quarter 2025 Financial Results and Business Updates

Randomized 3-month REMAIN-1 Midpoint Cohort data expected in September 2025

What macro or sector trends could amplify or dampen the market reaction to this earnings release? How could the Q2 performance and upcoming data affect the company's partnership or acquisition prospects within the industry? Are there any forward‑looking guidance updates or milestones that could shift the risk/reward profile for the stock?

Symbol: FRAY

28 days ago

Lumentum Announces Fourth Quarter and Full Fiscal Year 2025 Results

SAN JOSE, Calif.--(BUSINESS WIRE)--Lumentum Holdings Inc. (“Lumentum” or the “Company”) today reported results for its fourth quarter and full fiscal year ended June 28, 2025. “In our fiscal fourth...

Is there any new product or technology rollout mentioned that could create a competitive advantage or disrupt the market? What macro‑economic or supply‑chain factors could affect the continuation of this demand trend for Lumentum's products? How might the sustained customer demand for AI data center products influence Lumentum's long‑term growth trajectory and market share?

Symbol: LUMN

28 days ago

Read more businesswire

GRAIL Reports Second Quarter 2025 Financial Results

Q2 U.S. Galleri Revenue Grew 21% Year-Over-Year to $34.2 Million Q2 Galleri Tests Sold Grew 29% Year-Over-Year to More Than 45,000 Detailed Results From First 25,000 Enrolled in PATHFINDER 2 to be ...

What are the potential impacts on GRAIL's long‑term growth trajectory and market share in the early‑detection market? What are the competitive risks from other companies developing multi-cancer early detection tests? How might regulatory developments or reimbursement changes affect future revenue?

Symbol: GRAIL

28 days ago

TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance

DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigatio...

Are there any risks or uncertainties highlighted in the release that could affect the stock's volatility in the short term? What is the current cash position and projected runway, and does it raise concerns about dilution from future financing? Did the company issue any forward-looking statements regarding potential FDA milestones or trial readouts that could move the stock?

Symbol: TLSI

28 days ago

Read more businesswire

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogen...

How does Lineage Cell Therapeutics' valuation compare to other all‑ogeneic cell therapy companies after this release? What is the expected market size for the neurological and ophthalmic indications the company is targeting? Did the company address any potential risks or challenges that could impact the upcoming trial readouts?

Symbol: LCTX

28 days ago

Read more businesswire